THE EFFECT OF BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (bDMARDs) IN TARGETING DISEASE REMISSION IN AXIAL SPONDYLOARTHRITIS (axSpA): A SYSTEMATIC LITERATURE REVIEW (SLR)

被引：0
|
作者：
Cruz-Machado, A. R. [1 ,2 ]
Manica, S. R. [3 ]
Silva, J. L. [4 ]
Pimentel-Santos, F. M. [3 ]
Tavares-Costa, J. [4 ]
Vieira-Sousa, E. [1 ,2 ]
机构：
[1] Hosp Santa Maria, CHLN, Serv Reumatol & Doencas Osseas Metab, Lisbon, Portugal
[2] IMM, UIR, Lisbon, Portugal
[3] Ctr Hosp Lisboa Ocidental, Hosp Egas Moniz, Rheumatol Dept, Lisbon, Portugal
[4] Rheumatol Dept, Unidade Local Saude Alto Minho, Ponte do Lima, Portugal
来源：
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | 2018年 / 36卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P88
引用
收藏
页码：731 / 731
页数：1
相关论文
共 50 条
  • [21] Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis
    Alex R Kemper
    Heather A Van Mater
    Remy R Coeytaux
    John W Williams
    Gillian D Sanders
    BMC Pediatrics, 12
  • [22] Risk of cutaneous herpes zoster in patients with spondyloarthritis treated with conventional and biologic disease-modifying antirheumatic drugs
    Wong, Sabrina Ching Tung
    Li, Iris Wai Sum
    Ng, Alexandra Hoi Yan
    Lau, Chak Sing
    Chung, Ho Yin
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2020, 23 (02) : 189 - 196
  • [23] Sex Differences in Time to Initiate Nonsteroidal Anti-Inflammatory Drugs or Biologic Disease-Modifying Antirheumatic Drugs Among Patients With Axial Spondyloarthritis
    Shridharmurthy, Divya
    Lapane, Kate L.
    Baek, Jonggyu
    Nunes, Anthony P.
    Weisman, Michael H.
    Kay, Jonathan
    Liu, Shao-Hsien
    ARTHRITIS CARE & RESEARCH, 2024, 76 (08) : 1149 - 1161
  • [24] A clinical and economic review of disease-modifying antirheumatic drugs
    Gabriel, SE
    Coyle, D
    Moreland, LW
    PHARMACOECONOMICS, 2001, 19 (07) : 715 - 728
  • [25] A Clinical and Economic Review of Disease-Modifying Antirheumatic Drugs
    Sherine E. Gabriel
    Douglas Coyle
    Larry W. Moreland
    PharmacoEconomics, 2001, 19 : 715 - 728
  • [26] Targets of biologic disease-modifying antirheumatic drugs and risk of multiple myeloma
    Calip, Gregory S.
    Patel, Pritesh R.
    Sweiss, Karen
    Wu, Zhaoju
    Zhou, Jifang
    Asfaw, Alemseged A.
    Adimadhyam, Sruthi
    Lee, Todd A.
    Chiu, Brian C-H
    INTERNATIONAL JOURNAL OF CANCER, 2020, 147 (05) : 1300 - 1305
  • [27] Annual Cost of Biologic Disease-modifying Antirheumatic Drugs for Rheumatoid Arthritis
    Hosseini, Roya
    Brown, Lawrence
    Fleming, Marc
    Rodriguez-Monguio, Rosa
    Seoane-Vazquez, Enrique
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 2161 - 2162
  • [28] Systematic Review and Metaanalysis of Pharmacological Interventions in Adult-Onset Still Disease and the Role of Biologic Disease-Modifying Antirheumatic Drugs
    Ruscitti, Piero
    McGonagle, Dennis
    Garcia, Viviam Canon
    Rabijns, Hilde
    Toennessen, Katrin
    Chappell, Mary
    Edwards, Mary
    Miller, Paul
    Hansell, Neil
    Moss, Joe
    Graziadio, Sara
    Feist, Eugen
    JOURNAL OF RHEUMATOLOGY, 2024, 51 (05) : 442 - 451
  • [29] Comparative Efficacy of Biologic Disease-Modifying Anti-Rheumatic Drugs for Non-Radiographic Axial Spondyloarthritis: A Systematic Literature Review and Bucher Indirect Comparisons
    Nurullah Akkoç
    Carlos H. Arteaga
    Simone E. Auteri
    Marissa Betts
    Kyle Fahrbach
    Mindy Kim
    Sandeep Kiri
    Binod Neupane
    Karl Gaffney
    Philip J. Mease
    Rheumatology and Therapy, 2023, 10 : 307 - 327
  • [30] Comparative Efficacy of Biologic Disease-Modifying Anti-Rheumatic Drugs for Non-Radiographic Axial Spondyloarthritis: A Systematic Literature Review and Bucher Indirect Comparisons
    Akkoc, Nurullah
    Arteaga, Carlos H.
    Auteri, Simone E.
    Betts, Marissa
    Fahrbach, Kyle
    Kim, Mindy
    Kiri, Sandeep
    Neupane, Binod
    Gaffney, Karl
    Mease, Philip J.
    RHEUMATOLOGY AND THERAPY, 2023, 10 (02) : 307 - 327
12345